You are viewing the site in preview mode

Skip to main content

Table 1 TUB study participant characteristicsa

From: Design, creation, and use of the Test Us Bank (TUB) COVID-19 sample biorepository

Characteristic

Overall number of participants

SARS-CoV-2 PCR positive

SARS-CoV-2 PCR negative

 

(n=1814)

(n=561)

(n=1253)

Demographics

n or median

% or IQR

n or median

% or IQR

n or median

% or IQR

Age at registration

39

(27, 56)

38

(29, 54)

40

(27, 56)

Sex: Female

1090

60

340

61

750

60

Raceb

      

White

1201

74

353

79

848

72

Black/African

158

9.7

27

6.0

131

11

Asian

89

5.5

12

2.7

77

6.6

Native American

4

0.25

2

0.45

2

0.17

Pacific Islander

8

0.49

2

0.45

6

0.51

Other

82

5.1

27

6.0

55

4.7

Unknown

23

1.4

9

2.0

14

1.2

More than one

58

3.6

15

3.4

43

3.7

Ethnicityb

Yes: Mexican, Mexican American or Chicano

59

3.6

19

4.3

40

3.4

Yes: Puerto Rican

39

2.4

17

3.8

22

1.9

Yes: Cuban

1

0.06

0

0

1

0.09

Yes: Other or Mixed Hispanic, Latino or Spanish origin

92

5.7

28

6.3

64

5.4

Don't know

9

0.55

1

0.22

8

0.68

Prefer not to answer

8

0.49

0

0

8

0.68

Site

Iowa

746

41

237

42

509

41

JHU

113

6.2

49

8.7

64

5.1

Kansas

21

1.2

0

0

21

1.7

Morehouse

189

10

3

0.53

186

15

NU

145

8.0

66

12

79

6.3

Oregon

89

4.9

0

0

89

7.1

Stellenbosch

191

11

114

20

77

6.2

UML

109

6.0

8

1.4

101

8.1

UMass Chan

211

12

84

15

127

10

COVID-19 Symptoms

Scratchy throatb

0

0

0

0

0

0

Sore throat

105

5.8

65

12

40

3.2

Cough

469

26

320

57

149

12

Runny nose

464

26

281

50

183

15

Fever/chills

262

14

182

32

80

6.4

High temperature

67

3.7

55

9.8

12

0.96

Muscle aches

108

6.0

70

12

38

3.0

Nausea/vomiting/diarrhea

163

9.0

120

21

43

3.4

Shortness of breath

161

8.9

112

20

49

3.9

Unable to taste/smell

225

12

185

33

40

3.2

Red eyesb

0

0

0

0

0

0

Time from symptom onset (days)

6

(3, 8)

6

(4, 8)

5

(2, 10)

High blood pressure or hypertension

395

22

120

21

276

22

Diabetes

202

11

42

7.5

160

13

Coronary artery disease or angina

55

3.1

16

2.9

39

3.2

Heart attack

37

2.1

9

1.6

28

2.3

Congestive heart failure

21

1.2

8

1.5

13

1.1

Stroke or TIA

33

1.9

7

1.3

26

2.2

COPD

44

2.5

11

2.0

33

2.7

Asthma

129

7.1

41

7.3

88

7.0

Cancer undergoing active treatment

46

2.5

17

3.0

29

2.3

Immunodeficiency

25

1.4

12

2.2

13

1.0

Chronic HIV infection

15

0.83

5

0.89

10

0.80

Anemia or other blood disorder

114

6.3

29

5.2

85

6.8

Decreased kidney function or failure

32

1.8

14

2.5

18

1.4

CHD

0

0

0

0

0

0

CF

0

0

0

0

0

0

CLD BPD

0

0

0

0

0

0

Sickle cell anemia

2

0.11

0

0

2

0.16

Physical or mental condition(s) that limit ability to perform daily activitiesb

73

4.5

17

3.8

56

4.8

Deaf or have serious difficulty hearingb

7

9.6

2

12

5

8.9

Blind or have serious difficulty seeingb

9

12

2

12

7

13

Serious difficulty concentrating, remembering, or making decisionsb

32

44

9

53

23

41

Serious difficulty walking or climbing stairsb

25

34

5

29

20

36

Difficulty dressing or bathingb

8

11

1

5.9

7

13

Difficulty doing errands aloneb

27

37

8

47

19

34

Mental illness

397

25

134

31

263

23

Primary SARS-CoV-2 Vaccine Series (2 shots)

1504

83

480

86

1024

82

AstraZeneca

4

0.27

0

0

4

0.39

Janssen

182

12

92

19

90

8.8

Moderna

462

31

108

22

354

35

Novavax

1

0.07

0

0

1

0.10

Pfizer

834

55

277

58

557

54

Booster SARS-CoV-2 Vaccinec

379

25

121

25

258

25

  1. aPatient Characteristics not available for CCTS Samples
  2. bNot recorded for samples from Stellenbosch University
  3. cSubset of SARS-CoV-2 vaccinated participants
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us